Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 19.19 Billion JPY | 51.03% |
| 2022 | 11.2 Billion JPY | -13.82% |
| 2021 | 13 Billion JPY | 81.8% |
| 2020 | 7.15 Billion JPY | -15.76% |
| 2019 | 8.49 Billion JPY | -9.8% |
| 2018 | 9.41 Billion JPY | 1.81% |
| 2017 | 9.24 Billion JPY | 42.01% |
| 2016 | 6.51 Billion JPY | -7.92% |
| 2015 | 7.07 Billion JPY | 183.51% |
| 2014 | 2.49 Billion JPY | 134.84% |
| 2013 | 1.06 Billion JPY | -58.94% |
| 2012 | 2.58 Billion JPY | 0.61% |
| 2011 | 2.57 Billion JPY | 1.14% |
| 2010 | 2.54 Billion JPY | -3.95% |
| 2009 | 2.64 Billion JPY | -28.45% |
| 2008 | 3.69 Billion JPY | -46.05% |
| 2007 | 6.85 Billion JPY | -0.63% |
| 2006 | 6.9 Billion JPY | 54.8% |
| 2005 | 4.45 Billion JPY | 124.59% |
| 2004 | 1.98 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.69 Billion JPY | -2.37% |
| 2024 Q3 | 5.73 Billion JPY | 0.69% |
| 2024 Q1 | 5.83 Billion JPY | -6.76% |
| 2023 Q2 | 3.27 Billion JPY | 16.31% |
| 2023 FY | 16.92 Billion JPY | 51.03% |
| 2023 Q3 | 6.02 Billion JPY | 84.03% |
| 2023 Q1 | 2.81 Billion JPY | 4.61% |
| 2023 Q4 | 6.25 Billion JPY | 3.78% |
| 2022 FY | 11.2 Billion JPY | -13.82% |
| 2022 Q4 | 2.69 Billion JPY | -3.41% |
| 2022 Q3 | 2.78 Billion JPY | 3.45% |
| 2022 Q2 | 2.69 Billion JPY | -11.33% |
| 2022 Q1 | 3.03 Billion JPY | -47.88% |
| 2021 FY | 13 Billion JPY | 81.8% |
| 2021 Q4 | 5.82 Billion JPY | 119.72% |
| 2021 Q3 | 2.65 Billion JPY | 15.0% |
| 2021 Q1 | 2.21 Billion JPY | 9.63% |
| 2021 Q2 | 2.3 Billion JPY | 3.92% |
| 2020 FY | 7.15 Billion JPY | -15.76% |
| 2020 Q1 | 1.43 Billion JPY | -40.83% |
| 2020 Q2 | 1.88 Billion JPY | 31.77% |
| 2020 Q3 | 1.81 Billion JPY | -4.08% |
| 2020 Q4 | 2.02 Billion JPY | 11.82% |
| 2019 Q2 | 2.07 Billion JPY | 11.17% |
| 2019 Q1 | 1.86 Billion JPY | -31.42% |
| 2019 FY | 8.49 Billion JPY | -9.8% |
| 2019 Q3 | 2.13 Billion JPY | 3.33% |
| 2019 Q4 | 2.42 Billion JPY | 13.14% |
| 2018 Q3 | 2.93 Billion JPY | 12.18% |
| 2018 FY | 9.41 Billion JPY | 1.81% |
| 2018 Q2 | 2.61 Billion JPY | -8.94% |
| 2018 Q1 | 2.87 Billion JPY | 14.95% |
| 2018 Q4 | 2.71 Billion JPY | -7.56% |
| 2017 Q1 | 2.02 Billion JPY | 133.53% |
| 2017 FY | 9.24 Billion JPY | 42.01% |
| 2017 Q4 | 2.5 Billion JPY | 37.64% |
| 2017 Q3 | 1.81 Billion JPY | -11.41% |
| 2017 Q2 | 2.05 Billion JPY | 1.18% |
| 2016 FY | 6.51 Billion JPY | -7.92% |
| 2016 Q3 | 1.48 Billion JPY | -30.04% |
| 2016 Q4 | 868 Million JPY | -41.67% |
| 2016 Q2 | 2.12 Billion JPY | -23.49% |
| 2016 Q1 | 2.78 Billion JPY | 96.61% |
| 2015 FY | 7.07 Billion JPY | 183.51% |
| 2015 Q1 | 1.6 Billion JPY | 466.4% |
| 2015 Q2 | 1.42 Billion JPY | -11.37% |
| 2015 Q3 | 1.45 Billion JPY | 2.04% |
| 2015 Q4 | 1.41 Billion JPY | -2.62% |
| 2014 Q4 | 283.46 Million JPY | -9.21% |
| 2014 Q1 | -1.08 Billion JPY | -251.18% |
| 2014 FY | 2.49 Billion JPY | 134.84% |
| 2014 Q2 | 292.88 Million JPY | 127.0% |
| 2014 Q3 | 312.22 Million JPY | 6.6% |
| 2013 Q4 | 717.41 Million JPY | -0.59% |
| 2013 FY | 1.06 Billion JPY | -58.94% |
| 2013 Q2 | 707.51 Million JPY | 4.15% |
| 2013 Q1 | 679.33 Million JPY | 9.26% |
| 2013 Q3 | 721.71 Million JPY | 2.01% |
| 2012 Q1 | 662.35 Million JPY | 8.04% |
| 2012 FY | 2.58 Billion JPY | 0.61% |
| 2012 Q2 | 692.12 Million JPY | 4.49% |
| 2012 Q4 | 621.73 Million JPY | 4.76% |
| 2012 Q3 | 593.48 Million JPY | -14.25% |
| 2011 Q4 | 613.04 Million JPY | -2.98% |
| 2011 Q3 | 631.87 Million JPY | -4.82% |
| 2011 Q2 | 663.85 Million JPY | -5.89% |
| 2011 Q1 | 705.42 Million JPY | 11.07% |
| 2011 FY | 2.57 Billion JPY | 1.14% |
| 2010 Q1 | 689.03 Million JPY | 8.8% |
| 2010 Q2 | 597.99 Million JPY | -13.21% |
| 2010 Q3 | 603.56 Million JPY | 0.93% |
| 2010 FY | 2.54 Billion JPY | -3.95% |
| 2010 Q4 | 635.12 Million JPY | 5.23% |
| 2009 Q2 | 689.06 Million JPY | 18.71% |
| 2009 Q3 | 635.27 Million JPY | -7.81% |
| 2009 Q4 | 633.28 Million JPY | -0.31% |
| 2009 FY | 2.64 Billion JPY | -28.45% |
| 2009 Q1 | 580.48 Million JPY | -46.93% |
| 2008 Q4 | 1.09 Billion JPY | 14.6% |
| 2008 FY | 3.69 Billion JPY | -46.05% |
| 2008 Q3 | 954.39 Million JPY | 0.0% |
| 2007 FY | 6.85 Billion JPY | -0.63% |
| 2006 FY | 6.9 Billion JPY | 54.8% |
| 2005 FY | 4.45 Billion JPY | 124.59% |
| 2004 FY | 1.98 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -1393.998% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -3226.89% |
| GNI Group Ltd. | 9.32 Billion JPY | -105.85% |
| Linical Co., Ltd. | 2.7 Billion JPY | -609.377% |
| Trans Genic Inc. | 2.15 Billion JPY | -788.497% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -1186.918% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -524.864% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -933.401% |
| AnGes, Inc. | 8.9 Billion JPY | -115.564% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -1934.82% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -4546.602% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -1867.456% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -647.398% |
| CanBas Co., Ltd. | 278 Million JPY | -6802.878% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -1581.07% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -955.585% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -1096.561% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -708.319% |
| PeptiDream Inc. | 9.68 Billion JPY | -98.095% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -878.786% |
| Ribomic Inc. | 1.1 Billion JPY | -1635.566% |
| SanBio Company Limited | 4.53 Billion JPY | -322.78% |
| Healios K.K. | 3.48 Billion JPY | -450.33% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -1561.849% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -1338.029% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -1267.332% |
| StemRIM | 2.07 Billion JPY | -824.374% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -877.338% |
| FunPep Company Limited | 313.82 Million JPY | -6014.951% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -1903.106% |
| Stella Pharma Corporation | 963.98 Million JPY | -1890.695% |
| TMS Co., Ltd. | 943.25 Million JPY | -1934.449% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -1660.628% |
| Cuorips Inc. | 598.11 Million JPY | -3108.397% |
| K Pharma,Inc. | 543.94 Million JPY | -3427.95% |
| Takara Bio Inc. | 23.9 Billion JPY | 19.724% |
| ReproCELL Incorporated | 1.51 Billion JPY | -1167.491% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -1520.791% |
| StemCell Institute Inc. | 1.16 Billion JPY | -1551.29% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -1160.612% |
| CellSeed Inc. | 804.93 Million JPY | -2284.055% |